Tenofovir toxicity: association with Inosine Triphosphate Pyrophosphohydrolase activity and ITPA genotype

Tenofovir toxicity: association with Inosine Triphosphate Pyrophosphohydrolase activity and ITPA genotype - TenofoToxITP

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45178

Enrollment

100

Registered

2015-10-30

Start date

2016-04-18

Completion date

Unknown

Last updated

2024-04-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bijwerkingen medicatie Inosine triphosphate pyrophosphohydrolase deficiency

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: HIV-infected patients, aged over 18 years, who were or are still being treated with a anti-retroviral treatment containing tenofovir.

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

Measure	Time frame
Association between ITPase activity and nephrotoxicity, bone toxicity and recovery of nephrotoxicity and bone toxicity during and after tenofovir containing antiretroviral treatment for HIV.	—

Secondary

Measure	Time frame
Association between ITPA genotype and nephrotoxicity, bone toxicity and recovery of nephrotoxicity and bone toxicity during and after tenofovir containing antiretroviral treatment for HIV.	—

Countries

Netherlands

Outcome results